索拉非尼联合同期姑息放疗的I期剂量递增研究:TAP研究
该I期研究在胸、腹、盆腔三个解剖队列中独立递增索拉非尼剂量,同期给予30Gy/10次姑息放疗,评估耐受性和最大耐受剂量。因索拉非尼相关全身毒性导致10例显著中断用药,仅观察到3例剂量限制性毒性,试验因入组缓慢提前终止,最大耐受剂量未能确定。
要点
- 索拉非尼联合同期30Gy/10次姑息放疗时,索拉非尼相关全身毒性导致10例显著中断用药。
- 三队列各观察到1例剂量限制性毒性:胸段3级食管炎、腹段转氨酶升高、盆腔5级肠穿孔。
- 因入组缓慢和索拉非尼相关全身毒性,最大耐受剂量未能确定,联合方案不值得进一步研究。
核心结论
- 索拉非尼联合同期30Gy/10次姑息放疗的最大耐受剂量因索拉非尼相关全身毒性未能确定。
- 观察到严重放疗相关毒性,提示该同期联合方案不值得进一步研究。
研究设计与样本
- I期剂量递增研究,在不可治愈癌症患者中按照射部位(胸、腹、盆腔)分三个独立队列递增索拉非尼剂量。
- 索拉非尼第1-28天给药,放疗30Gy分10次于第8-12天和第15-19天进行。
- 剂量限制性毒性定义为归因于放疗的急性3级及以上毒性。
主要发现
- 胸、腹、盆腔队列分别入组14、16、4例患者,分别达到剂量水平3、3、2。
- 索拉非尼相关全身毒性导致10例患者显著中断索拉非尼。
- 共3例剂量限制性毒性,每队列1例:胸段3级食管炎、腹段转氨酶升高、盆腔5级肠穿孔(肿瘤侵犯肠道患者)。
- 12例患者发生2级放射性皮炎。
- 试验因入组缓慢和索拉非尼相关全身毒性妨碍放疗相关剂量限制性毒性有效评估而提前终止。
关键数值与推荐
- 放疗剂量为30Gy分10次,索拉非尼第1-28天给药。
- 剂量限制性毒性定义为归因于放疗的急性3级及以上毒性。
- 胸、腹、盆腔队列分别达到剂量水平3、3、2。
临床怎么用
- 索拉非尼联合同期30Gy/10次姑息放疗时,索拉非尼相关全身毒性常见且可导致显著中断用药。
- 需警惕严重放疗相关毒性,包括3级食管炎、转氨酶升高和5级肠穿孔。
- 该同期联合方案因毒性及评估困难,不推荐进一步临床研究。
局限性
- 试验因入组缓慢和索拉非尼相关全身毒性提前终止,最大耐受剂量未能确定。
- 索拉非尼相关全身毒性妨碍了放疗相关剂量限制性毒性的有效评估。
- 盆腔队列仅入组4例患者,样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: To evaluate the tolerability and maximum tolerated dose (MTD) of sorafenib administered concurrently with palliative radiotherapy. MATERIAL AND METHODS: In patients with incurable cancer, sorafenib was escalated independently in three cohorts based on irradiation site: thorax, abdomen or pelvis. Sorafenib was administered days 1-28 and radiotherapy (30Gy in 10 fractions) was delivered days 8-12 and 15-19. Dose-limiting toxicities (DLT) were acute grade 3+ toxicities attributable to radiotherapy. RESULTS: For the thorax, abdomen and pelvis cohorts, 14, 16 and 4 patients were recruited, and Dose Levels 3, 3 and 2 were reached, respectively. Sorafenib-related systemic toxicity led to significant sorafenib interruption in 10 patients. There were 3 DLTs in total, one per cohort: grade 3 oesophagitis (thoracic), transaminase elevation (abdominal) and grade 5 bowel perforation (pelvic; patient with tumour invading bowel). Grade 2 radiation dermatitis developed in 12 patients. The trial was terminated early as slow accrual and sorafenib-related systemic toxicity prevented efficient evaluation of RT-related DLTs. CONCLUSIONS: The MTD of sorafenib when used with 30Gy in 10 fractions was not established due to sorafenib-related systemic toxicity. Severe radiotherapy-related toxicities were also observed. These events suggest this concurrent combination does not warrant further study.
引用
- Murray L, Longo J, Wan J, et al. Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study. Radiother Oncol. 2017. PMID: 28668472. doi:10.1016/j.radonc.2017.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。